Beta Blockers

Labetalol EP impurity D is a metabolite of labetalol that is used as an impurity standard for HPLC. This impurity has been identified in the drug product and also in the drug development process. Labetalol EP impurity D is one of many metabolites that can be formed by cytochrome P450 enzymes. Labetalol EP impurity D is a natural metabolite of labetalol, which can be found in the urine of humans and other mammals. It is also present in various plants and fungi, including mushrooms, lichens, yeast, and barley. Synthetic labetalol EP impurity D can also be produced by various chemical reactions.

Impurity Atorvastatin lactam phenanthrene calcium salt impurity Applications Atorvastatin (A791750) impurity. A stable Atorvastatin formulation.

Applications An enantiomeric impurity of Ezetimibe (E975005).

Stability Light Sensitive Applications Moxidectin-d3 is a the labelled form of Moxidectin (M744800). Moxidectin is a macrocyclic lactone and semisynthetic derivative of nemadectin. Moxidectin is a parasiticide used for the prevention and control of heartworm and intestinal worms. Moxidectin is found in veterinary medicine used to treat animals such as dogs, cats, horses, cattle and sheep. Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package References Bisset, S.A. et al.: New Zeal. Vet. J., 40, 97 (1992); Monahan, C.M. et al.: Vet. Parasitol., 63, 225 (1996); Glickman, L.T. et al.: Int. J. Appl. Res. Vet. Med., 3, 49 (2005)

Applications A metabolite of Simvastin (S485000). A competitive inhibitor of HMG-CoA reductase. References Hoffman, W.F., et al.: J. Med. Chem., 29, 849 (1986), Mol, M.J., et al.: Lancet, 2, 936 (1986),

Applications N-Desmethyl analog of Rosuvastatin Lactone (R700550); an intermediate in the production of Rosuvastatin (R700500) derivatives.

Stability Hygroscopic Applications Labeled Dabigatran Etexilate-d11, an oral anticoagulant and direct thrombin inhibitor. References Mangiafico, R. et al.: Curr. Med. Chem., 19, 4688 (2012); Hu, Z. et al.: Anal. Bioanal. Chem., 405, 1695 (2013);

Applications Labelled Atorvastatin intermediate as inhibitor of MAP kinase and/or HMG-CoA reductase for the treatment of inflammation. References Boyd, R., et al.: J. Clin. Pharmacol., 40, 91, (2000), Bogman, K., et al.: Br. J. Pharmacol., 132, 1183 (2001), Backman, J., et al.: Clin. Pharmacol. Ther., 72, 685 (2002), Kalvass, J., et al.: Drug Metab. Dispos., 35, 455 (2007),

Stability Light Senstiive Applications D,L-Adrenochrome is the substance mainly responsible for the red colours produced during the mild oxidation of adrenaline References Costa, V., et al.: Chem. Res. Toxicol., 20, 1183 (2007), Sotomayor-Zarate, R., et al.: Biol Reproduc., 78, 673 (2008),

Applications A selective β-adrenergic blocker. Used as an antihypertensive. References Tattersfield, A.E., et al.: Brit. J. Clin. Pharmacol., 18, 343 (1984), Kohli, R.S., et al.: Eur. Heart J., 6, 845 (1985), Zachariah, P.K., et al.: Clin. Ther., 15, 779 (1993),

Applications A metabolite of Diltiazem (D460620), an antianginal, antihypertensive pharmaceutical. Diltiazem regulates Calcium release from intracellular stores in neutrophils. References Li, R., et al.: J. Med. Chem., 35, 3246 (1992),

Applications Sacubitril is an antihypertensive drug used in combination with valsartan. The combination drug, valsartan/sacubitril, known during trials as LCZ696 and marketed under the brand name, Entresto, is a treatment for heart failure. References McMurray, J., et al.: N. Eng. J. Med., 371 (2014)

Applications A new antihypertensive agent; exhibited a natriuretic effect comparable to that of hydrochlorothiazide and furosemide within 7 h. A furopyridine derivative with antihypertensive and diuretic properties. References Braquet, P., et al.: Lancet, 1, 1218 (1983), Guinot, P., et al.: Arzneim.-Forsch., 35, 1714 (1985), Clement, D., et al.: Int. J. Clin. Pharmacol. Res., 8, 9 (1988), Lize, J.M., et al.: Therapie, 42, 399 (1987),

Applications A labelled β1-Adrenergic blocker. Used as an antihypertensive. References Van de Water, A., et al.: J. Cardiovasc. Pharmacol., 11, 552 (1988), De Cree, J., et al.: Angiology, 41, 95 (1990)

Applications A substituted 2,4,6-triiodobenzoic acid, an excellent contrast media for ventriculography, radiculography, lumbar myelography and x-rays of the cardiovascular system. Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package References Frocrain, L., et al.: Radiology, 170, 531 (1989), van Waes, P.F., et al.: Eur. J. Radiology, 9,179 (1989),